Tumor genetics, particularly mutations in the v-raf murine sarcoma viral oncogene homolog B1 (BRAF), Neuroblastoma Ras viral oncogene homolog (NRAS), and receptor tyrosine kinase proto-oncogene (c-KIT) genes, can impact how effectively T-VEC targets and destroys cancer cells. This evidence concerns the gene BRAF and neoplasm.